Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial

Additional reductions in low-density lipoprotein-cholesterol (LDL-C) via antidiabetic therapies should be considered in statin-using patients with sub-optimal LDL-C levels. We compared the efficacy of anagliptin and sitagliptin, two antidiabetic therapies, in reducing LDL-C in type 2 diabetic patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Morimoto, Takeshi, Sakuma, Ichiro, Sakuma, Mio, Tokushige, Akihiro, Natsuaki, Masahiro, Asahi, Tomohiro, Shimabukuro, Michio, Nomiyama, Takashi, Arasaki, Osamu, Node, Koichi, Ueda, Shinichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561974/
https://www.ncbi.nlm.nih.gov/pubmed/31189978
http://dx.doi.org/10.1038/s41598-019-44885-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561974/
https://www.ncbi.nlm.nih.gov/pubmed/31189978
http://dx.doi.org/10.1038/s41598-019-44885-x

Ejemplares similares